Alkermes ( (ALKS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alkermes (ALKS) shares are sliding today as traders lock in gains and the stock pulls back from technically overbought levels, with the RSI recently topping 80. The move looks like a normal correction after a sharp run-up rather than a shift in the company’s fundamentals.
The stock had soared to a new 52-week high in the previous session after Eli Lilly’s $6.3 billion deal for Centessa Pharmaceuticals boosted optimism for the orexin receptor agonist space, where Alkermes competes. Investors also reacted positively to Alkermes’ launch of Phase 3 “Brilliance” trials for its narcolepsy drug candidate, alixorexton.
No major changes to Wall Street price targets have emerged so far, but today’s pullback may prompt analysts to reassess their outlook if volatility persists. For now, the move highlights how quickly momentum names can reverse once short-term traders begin to take profits.
More about Alkermes
YTD Price Performance: 25.27%
Average Trading Volume: 2,385,431
Technical Sentiment Signal: Buy
Current Market Cap: $5.84B
For further insights into ALKS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.